SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Cytokinetics Investors

Leading national securities‑law firm Faruqi & Faruqi, LLP has opened an investigation into potential claims on behalf of investors in Cytokinetics, Incorporated (NASDAQ: CYTK), urging those who purchased the company’s securities between December 27, 2023 and May 6, 2025 to inquire about their legal rights. The firm highlights that on May 6, 2025, Cytokinetics revealed it omitted a required Risk Evaluation and Mitigation Strategy (REMS) from its New Drug Application for aficamten — despite earlier statements that approval from the U.S. Food and Drug Administration was expected in the second half of 2025. The omission may have misled investors, according to the complaint, and resulted in artificially inflated stock prices followed by significant losses. Investors with information or concerns are encouraged to contact Faruqi & Faruqi directly and note the impending November 17, 2025 deadline to seek lead‑plaintiff status in the federal class action. #Cytokinetics #SecuritiesLitigation #InvestorAlert #PharmaRegulation #SlimScan #GrowthStocks #CANSLIM